You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: available evidence does not support the use of β blockers as first line treatment for hypertension

https://doi.org/10.1136/ebm.12.4.112

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Wiysonge C, Bradley H, Mayosi B, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev 2007;(1):CD002003.
    OpenUrlPubMed

    
 
 Q In adults with hypertension, what is the effectiveness and safety of β blockers (BBs)?

    Clinical impact ratings GP/FP/Primary care ★★★★★★★ IM/Ambulatory care ★★★★★★☆ Nephrology ★★★★★★☆ Cardiology ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    PubMed, EMBASE/Excerpta Medica, Cochrane Database of Systematic Reviews, Cochrane Register of Controlled Trials, York Database of Abstracts and Reviews of Effectiveness, reference lists, experts in the field, and drug manufacturers.

    Embedded ImageStudy selection and assessment:

    randomised controlled trials (RCTs) that evaluated BBs in adults with hypertension. Study methods were assessed for quality, including allocation concealment, blinding, and completeness of follow up. 13 RCTs (91 561 patients) met the selection criteria.

    Embedded ImageOutcomes:

    total mortality. Secondary outcomes included coronary heart disease, cardiovascular disease, stroke, and adverse drug reactions.

    MAIN RESULTS

    BBs do not reduce mortality (table) or coronary heart disease (see table at www.evidence-basedmedicine.com) more than placebo, diuretics, or renin angiotensin system …

    View Full Text

    Footnotes

    • For correspondence: Dr C S Wiysonge, Ministry of Public Health, Yaoundé, Cameroon. wiysonge{at}yahoo.com

    • Source of funding: Medical Research Council (CSW) South Africa.